Radioprotective agents for radiation therapy: future trends
Radioprotective agents for radiation therapy: future trends
复制标题
DOI：
10.2217/fon.14.175
复制
发表时间：
2014-01-01
期刊：
影响因子：
3.3
通讯作者：
Allison, Ron R.
中科院分区：
文献类型：
--
作者：
Johnke, Roberta M.;Sattler, Jennifer A.;Allison, Ron R.
目前只有两种放射防护化合物，amifostine和palifermin，获得美国FDA批准用于放射治疗。然而，已经报道了几种药物显示出治疗前景。这些试剂中的许多是自由基清除剂/抗氧化剂。超氧化物歧化酶和超氧化物歧化酶模拟物，氮氧化物和膳食抗氧化剂都在研究中。最近，药物开发的替代策略一直在发展，其重点是针对辐射后启动的一系列细胞损伤识别/修复反应。这些药物包括细胞因子/生长因子、血管紧张素转换酶抑制剂和凋亡调节剂，显示出对减轻辐射损伤具有显著影响的前景。在此，我们回顾了目前的文献发展的辐射防护剂，重点是化合物已被证明或潜在的有用性，在放射治疗。
Only two radioprotective compounds, amifostine and palifermin, currently have the US FDA approval for use in radiation therapy. However, several agents have been reported that show therapeutic promise. Many of these agents are free radical scavengers/antioxidants. Superoxide dismutase and superoxide dismutase mimetics, nitroxides and dietary antioxidants are all being investigated. Recently, alternative strategies of drug development have been evolving, which focus on targeting the series of cellular insult recognition/repair responses initiated following radiation. These agents, which include cytokines/growth factors, angiotensin-converting enzyme inhibitors and apoptotic modulators, show promise of having significant impact on the mitigation of radiation injury. Herein, we review current literature on the development of radioprotectors with emphasis on compounds with proven or potential usefulness in radiation therapy.